Enveric Biosciences Inc. (ENVB): Price and Financial Metrics
GET POWR RATINGS... FREE!
ENVB Stock Price Chart Interactive Chart >
ENVB Price/Volume Stats
| Current price | $2.88 | 52-week high | $34.33 |
| Prev. close | $3.00 | 52-week low | $1.57 |
| Day low | $2.87 | Volume | 43,100 |
| Day high | $3.20 | Avg. volume | 50,643 |
| 50-day MA | $2.60 | Dividend yield | N/A |
| 200-day MA | $6.29 | Market Cap | 5.98M |
Enveric Biosciences Inc. (ENVB) Company Bio
Enveric Biosciences Inc., formerly AMERI Holdings, Inc., is a patient-central biotechnology company. The Company is focused on enhancing lives of people affected by the side effects of cancer treatments, such as radiodermatitis and chemotherapy-induced peripheral neuropathy. The Company is engaged in leveraging its clinical developments derived from ... More
Latest ENVB News From Around the Web
Below are the latest news stories about ENVERIC BIOSCIENCES INC that investors may wish to consider to help them evaluate ENVB as an investment opportunity.
Enveric Biosciences to Present at the 6th Annual Neuroscience Innovation Forum and Biotech Showcase during "J.P. Morgan Health Care Week 2023"CAMBRIDGE, Mass., December 21, 2022--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression and addiction disorders, announced today that the company will present at the 6th Annual Neuroscience Forum and the Biotech Showcase™. Both events will be held live and are scheduled to coincide with the 41st Annual J.P. Morgan Health Care Conference in San Francisco |
Enveric Biosciences Announces Confidential Submission of Registration Statement for the Spin-off of its Cannabinoid Business to ShareholdersEnveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression and addiction disorders, today announced the confidential submission of a Form S-1 draft registration statement with the U.S. Securities and Exchange Commission (‘SEC’) for the spin-off its |
Enveric Biosciences to Participate in A.G.P.’s Virtual Biotech ConferenceCAMBRIDGE, Mass. — Enveric Biosciences (NASDAQ: ENVB) (”Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression and addiction disorders, today announced that Avani Kanubaddi, President & COO of Enveric Biosciences, will participate in A.G.P.’s Virtual Biotech Conference to be held from November 30, […] |
Enveric Biosciences to Participate in Wonderland: Miami on November 3-5, 2022CAMBRIDGE, Mass., November 01, 2022--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression and addiction disorders, today announced that Dr. Joseph Tucker, Chief Executive Officer of Enveric Biosciences, will participate in Wonderland: Miami hosted by Microdose to be held at the Mana Wynwood Convention Center in Miami, FL on November 3-5, 2022. |
Enveric abandons EVM101 psilocybin drug program in favor of EB-373 for anxiety disordersCannabis drugmaker Enveric Biosciences (ENVB) on Monday said it discontinued the development of its first generation EVM101 program of psilocybin targeting cancer… |
ENVB Price Returns
| 1-mo | 10.77% |
| 3-mo | -6.19% |
| 6-mo | -58.68% |
| 1-year | -90.71% |
| 3-year | -98.91% |
| 5-year | N/A |
| YTD | 38.46% |
| 2022 | -95.53% |
| 2021 | -78.17% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...